RA may differ in their treatment responses. We used data from a randomized controlled trial (RCT)-the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trial-to examine whether responses to intensive combination treatments in early RA differ by ACPA status. Methods: The CARDERA trial randomized 467 patients with early active RA to receive: (i) MTX (ii) MTX/ciclosporin (iii) MTX/prednisolone or (4) MTX/ciclosporin/prednisolone in a factorial-design. Patients were assessed 6 monthly for 2 years. In this analysis we evaluated 431 patients with archived serum available for ACPA status determination (using the anti-CCP2 ELISA assay). To minimize multiple testing we used a mixed-effects repeated measures ANOVA model to test for an interaction between ACPA and treatment on mean changes from baseline for each outcome (Larsen, DAS28, HAQ, EuroQol, PCS and MCS scores). When a significant interaction was present, mean changes in outcomes were compared by treatment group at each time point stratified by ACPA status using t-tests. Odds ratios (ORs) for the onset of new erosions with treatment were calculated stratified by ACPA. Results: Of the 431 RA cases, 310 (72%) were ACPA-positive; 121 (28%) were ACPA-negative. ACPA status influenced the effect of treatment on radiological progression, with a significant ACPA*treatment interactive effect on Larsen score changes seen in the ANOVA model (P < 0.001). ACPA-positive patients had significant reductions in Larsen score progression with all treatments; no effect was seen in ACPAnegative RA. ACPA-positive patients receiving triple therapy had the greatest benefits: mean Larsen score increases over 2 years were 3.66 (95% CI 2.27, 5.05) with triple therapy and 9.58 (95% CI 6.76, 12.39) with monotherapy; OR for new erosions with triple therapy vs monotherapy was 0.32 (95% CI 0.14, 0.72; P ¼ 0.003). ACPA-negative patients had minimal radiological progression irrespective of treatment strategy: mean Larsen score increases over 2 years comprised 1.70 (95% CI 0.29, 3.10) with triple therapy and 2.72 (95% CI 1.15, 4.29) with monotherapy; only 7% developed new erosions. The beneficial effects of high-dose corticosteroids on reducing disease activity and improving physical health were confined to ACPA-positive RA. Conclusion: ACPA status influences the need for, and response to, combination DMARDs and high-dose tapering corticosteroids in early RA. Combination DMARDs and corticosteroids only provided radiological, disease activity and physical health benefits in ACPA-positive patients. This suggests that current UK guidelines advocating combination DMARDs and corticosteroids in all early active RA patients require reconsideration.
FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS
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Methods:
Pts in GO-BEFORE were randomized to placebo(PBO)þMTX, GLM 100 mg þ PBO, GLM 50 mg þ MTX, or GLM 100 mg þ MTX q4w. PBO þ MTX pts crossed over to GLM þ MTX at weeks 28 (blinded early escape) or 52 (pts with 1 swollen/tender joint). Pts continued treatment at week 52 (start of longterm extension). After the last pt completed week 52 and unblinding occurred, PBO þ MTX pts could switch to GLM 50 mg þ MTX, MTX and corticosteroid use could be adjusted, and a one-time GLM dose change (50 to 100 mg or 100 to 50 mg) was permitted at investigator's discretion. The last GLM injection was at week 252. Observed efficacy results (ACR20/50/70, DAS28-CRP, HAQ-DI, radiographic) by randomized treatment group and cumulative safety data are reported through weeks 256 and 268, respectively. Results: Of 637 randomized pts, 3 were never treated; 419 continued treatment through week 252, and 215 pts withdrew (111 for AE, 23 for lack of efficacy, 20 lost to follow-up, 53 for other reasons, 8 deaths). 402 pts completed the safety follow-up through week 268. At week 256, 84.3% of all pts had an ACR20, 93.9% had DAS28-CRP EULAR response, and 80.6% had improvement in HAQ-DI 0.25. Mean changes from baseline in total vdH-S score were small and 64% of pts randomized to GLM þ MTX had no radiographic progression (ÁvdH-S 0). The most common AEs were upper respiratory tract infection (29.4%), nausea (19.6%), bronchitis (16.6%), and increased alanine aminotransferase (16.1%); 11.9% of pts had an injection-site reaction. Through week 268, 204/616 (33.1%) pts had an SAE; 17.5% of pts discontinued study agent due to AEs. Overall rates of serious infections, malignancies, and death were 12.2%, 3.4%, and 1.9%, respectively. Of 595 pts with available samples, 58 (9.7%) were positive for antibodies to GLM. Conclusion: The retention rate was high (66.1%) through 5 years. GLM þ MTX therapy resulted in maintained improvements in signs/ symptoms of RA and in physical function, and inhibited structural damage progression long-term. No new safety signals were detected through 5years in MTX-naïve RA pts. Disclosure statement: P.E. has received grants/research support from Janssen R&D, LLC. R.M.F. has received grants/research support from Janssen R&D, LLC. I.S. has received grants/research support from Janssen R&D, LLC. P.D. has received grants/research support from Janssen R&D, LLC. P.N. has received grants/research support from Janssen R&D, LLC. E.A. has received grants/research support from Janssen R&D, LLC. M.C. has received grants/research support from Janssen R&D, LLC. W.P. has received grants/research support from Janssen R&D, LLC. B.P.-E. has received grants/research support from Janssen R&D, LLC. C.H. is an employee of Janssen Global Services, LLC and may hold stock or stock options. T.G. is an employee of Janssen Global Services, LLC and may hold stock or stock options. Y.Z. is an employee of Janssen R&D, LLC and may hold stock or stock options. S.X. is an employee of Janssen R&D, LLC and may hold stock or stock options. E.C.H. is an employee of Janssen R&D, LLC and may hold stock or stock options. 
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